Jonas Ghouse, Vinicius Tragante, Ayesha Muhammad, Gustav Ahlberg, Morten W Skov, Dan M Roden, Ingileif Jonsdottir, Laura Andreasen, Pia Rengtved Lundegaard, Linea C Trudsø, Karina Banasik, Søren Brunak, Sisse R Ostrowski, Christian Torp-Pedersen, Ole V Pedersen, Erik Sørensen, Lars Køber, Kasper Iversen, Unnur Thorsteinsdottir, Gudmundur Thorgeirsson, Henrik Ullum, Daniel F Gudbjartsson, Jonathan D Mosley, Hilma Holm, Kari Stefansson, Henning Bundgaard, Morten Salling Olesen
AIMS: To search for sequence variants associated with ACEi discontinuation and to test their association with ACEi-associated adverse drug reactions (ADRs). METHODS AND RESULTS: A genome-wide association study (GWAS) on ACEi discontinuation was conducted, including 33 959 ACEi-discontinuers and 44 041 controls. Cases were defined as persons who switched from an ACEi treatment to an angiotensin receptor blocker. Controls were defined as persons who continued ACEi treatment for at least 1 year...
June 25, 2022: European Heart Journal